Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: Results of PAVIA, an open-label post-marketing survey in Spain

Current Medical Research and Opinion

Volumn 19, Issue 5, 2003, Pages 402-410

  Collantes Esteve, Eduardo ^a   Fernandez Perez, Cristina ^b  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Celecoxib; Osteoarthritis; Rofecoxib; Satisfaction; Switching

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ROFECOXIB;

ADULT; AGE; AGED; ARTHRALGIA; ARTICLE; CERVICAL SPINE; CLINICAL TRIAL; DEPRESSION; DIABETES MELLITUS; DISEASE DURATION; DISEASE EXACERBATION; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DRUG MARKETING; DRUG SURVEILLANCE PROGRAM; FEMALE; GASTROINTESTINAL SYMPTOM; HEALTH STATUS; HUMAN; KNEE DISEASE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OBESITY; OSTEOARTHRITIS; PATIENT COMPLIANCE; PATIENT SATISFACTION; PREDICTION; RISK FACTOR; SELF EVALUATION; SPAIN; STATISTICAL SIGNIFICANCE;

AGED; CYCLOOXYGENASE INHIBITORS; FEMALE; HEALTH STATUS; HUMANS; LACTONES; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OSTEOARTHRITIS; PAIN; PATIENT SATISFACTION; PRODUCT SURVEILLANCE, POSTMARKETING; PYRAZOLES; SPAIN; SULFONAMIDES; SULFONES;

EID: 0042734767     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079903125001938     Document Type: Article

References (16)

1. Malmstrom K, Daniels S, Kotey P, Seidenberg BC, Desjardins PJ. Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo- and active-comparator-controlled clinical trial. Clin Ther 1999;21:1653-63
2. Chang DJ, Fricke JR, Bird SR, Bohidar NR, Dobbins SR, Beba GP. Rofecoxib versus codeine/acetaminophen in postoperative dental pain: a double-blind, randomized, placebo- and active comparator-controlled clinical trial. Clin Ther 2001;23:1446-55
3. Ehrich EW, Dallob A, De Lepeleire I, Van Hecken A, Riendeau D, Yuan W, et al. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther 1999;65:336-47
4. Morrison BW, Daniels SE, Kotey P, Cantu N, Seidenberg BC. Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial. Obstet Gynecol 1999;94:504-8
5. Schnitzer TJ, Truiit K, Fleischman R, Dalgin P, Bock J, Zeng Q, et al. The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Clin Ther 1999;21:1688-702
6. Geba G, Weaver AL, Polis AB, Dixon ME, Schnitzer TJ, for the VACT Group. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee. A randomized trial. JAMA 2002;287:64-71
7. Myllykangas-Luosujarvi R, Lu HS, Chen SL, Choon D, Amante C, Chow CT, et al., for the Naproxen 901 OF and 901 OC study groups. Comparison of low-dose rofecoxib versus 1000 mg naproxen in patients with osteoarthritis. Results of two randomized treatment trials of six weeks duration. Scand J Rheumatol 2002;31:337-44
8. Bensen WG, Fiechtner J, McMillen JI, Zhao WW, Yu SS, Woods EM, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999;74:1095-105
9. Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: a randomised double-blind comparison. Lancet 1999;354:2106-11
10. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al., for the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8
11. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 2000;284:1247-55
12. Tacconelli S, Capone ML, Sciulii MG, Ricciotti E, Patrignani P. The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. Curr Med Res Opin 2002;18:503-51
13. Geba G, Weaver A, Polis A, Petruschke R, Schnitzer T. Pooled analysis of the VACT studies: the response of osteoarthritis patients to therapy with rofecoxib, celecoxib, or acetaminophen. 22nd Annual Scientific Meeting of the American Pain Society, March 20-23, 2003, Chicago, Illinois. Abstract 826.
14. Reuben SS, Connelly NR. Postoperative analgesic effects of celecoxib or rofecoxib after spinal fusion surgery. Anesth Analg 2000;91:1221-5
15. Wolfe F, Flowers N, Burke TA, Arguelles LM, Petitt D. Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis. J Rheumatol 2002;29:1015-22
16. American Pain Society. Recommendations for the management of pain in osteoarthritis. Update 2002. Anesth Analg 2002;24:124-6